NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated July 13, 2026

Cinacalcet

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

Cinacalcet is an oral calcimimetic used for secondary hyperparathyroidism in adults on dialysis and for hypercalcemia in parathyroid carcinoma or selected primary hyperparathyroidism patients. It lowers parathyroid hormone and serum calcium, so hypocalcemia, QT prolongation from hypocalcemia, seizures, and worsening heart failure symptoms are key safety concerns.

Publication status

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

Cinacalcet is an oral calcimimetic used for secondary hyperparathyroidism in adults on dialysis and for hypercalcemia in parathyroid carcinoma or selected primary hyperparathyroidism patients. NutriStack rates the supporting evidence as strong. Common adult dosing is Secondary hyperparathyroidism in adults on dialysis: start 30 mg orally once daily and titrate every 2 to 4 weeks by PTH and calcium. Parathyroid carcinoma or primary hyperparathyroidism: often 30 mg twice daily initially, titrated to calcium response., though a prescriber sets the actual dose. With long-term use it can deplete calcium. This profile indexes 3 sources.

What it's good for
  • Reduced PTH in dialysis-related secondary hyperparathyroidism1
  • Reduced hypercalcemia in parathyroid carcinoma
  • Reduced serum calcium in selected primary hyperparathyroidism when surgery is not appropriate2,3
  • Adjunctive control of CKD mineral and bone disorder parameters
What to watch for
  • Nausea
  • Vomiting
  • Diarrhea
  • Do not initiate if corrected serum calcium is below the lower limit of normal2,3
  • Known hypersensitivity to cinacalcet1,3

The bottom line

Evidence rating strong. Most-documented uses: reduced pth in dialysis-related secondary hyperparathyroidism, reduced hypercalcemia in parathyroid carcinoma, reduced serum calcium in selected primary hyperparathyroidism when surgery is not appropriate. 3 sources indexed (2012–2026), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Cinacalcet allosterically increases sensitivity of the calcium-sensing receptor on parathyroid cells to extracellular calcium. This suppresses parathyroid hormone secretion, which lowers serum calcium and can lower phosphorus in some settings. Metabolism involves CYP3A4, CYP2D6, and CYP1A2, and calcium changes require close biochemical monitoring.3,1

Class
Calcimimetic calcium-sensing receptor agonist
Absorption
Water-soluble; take with food
Dosing

Dosing & protocol.

Common range
Secondary hyperparathyroidism in adults on dialysis: start 30 mg orally once daily and titrate every 2 to 4 weeks by PTH and calcium. Parathyroid carcinoma or primary hyperparathyroidism: often 30 mg twice daily initially, titrated to calcium response.
Recommended form
Oral tablet taken with food or shortly after a meal

Take with food or shortly after a meal to improve exposure. Do not start if corrected serum calcium is below the lower limit of normal.

Depletions

What it depletes.

Nutrients this medication can lower over time, and what to replace.

Calcium

Significant

Cinacalcet intentionally lowers PTH and serum calcium and can cause clinically significant hypocalcemia.

Replace CalciumMonitor Corrected serum calciumOnset Days to weeks, especially after initiation or dose increase
Safety

Full safety detail.

Side effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Myalgia
  • Dizziness
  • Hypocalcemia
  • Paresthesias
  • Seizures in susceptible patients
  • QT prolongation secondary to hypocalcemia
  • Hypotension or worsening heart failure symptoms
  • Adynamic bone disease if PTH is oversuppressed

Contraindications

  • Do not initiate if corrected serum calcium is below the lower limit of normal2,3
  • Known hypersensitivity to cinacalcet1,3
  • Use caution with seizure disorders, long QT risk, heart failure, hepatic impairment, or other calcium-lowering therapies3
Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Randomized controlled trials

1
  • 1Effect of cinacalcet on cardiovascular disease in patients undergoing dialysisEVOLVE Trial Investigators · New England Journal of Medicine · 2012

    Large outcomes trial informs benefits and limitations of cinacalcet in dialysis-related secondary hyperparathyroidism.

Reviews & position papers

1
  • 2KDIGO 2017 Clinical Practice Guideline Update for CKD-MBDKidney Disease: Improving Global Outcomes · Kidney International Supplements · 2017

    Guideline supports individualized use of calcimimetics and avoidance of hypocalcemia or oversuppressed PTH.

Reference material

1
  • 3Cinacalcet Tablets US Prescribing InformationURLU.S. National Library of Medicine · DailyMed · 2026

    Labeling describes dosing, contraindication to initiation with low calcium, monitoring for hypocalcemia, and CYP interactions.

FAQ

Common questions.

Quick answers about Cinacalcet, drawn from the data on this page.

What is Cinacalcet?

Cinacalcet is an oral calcimimetic used for secondary hyperparathyroidism in adults on dialysis and for hypercalcemia in parathyroid carcinoma or selected primary hyperparathyroidism patients. It lowers parathyroid hormone and serum calcium, so hypocalcemia, QT prolongation from hypocalcemia, seizures, and worsening heart failure symptoms are key safety concerns.

What is Cinacalcet used for?

Commonly cited benefits of Cinacalcet include: Reduced PTH in dialysis-related secondary hyperparathyroidism; Reduced hypercalcemia in parathyroid carcinoma; Reduced serum calcium in selected primary hyperparathyroidism when surgery is not appropriate; Adjunctive control of CKD mineral and bone disorder parameters. NutriStack rates the overall evidence as strong.

What is a typical dose of Cinacalcet?

A typical adult dose of Cinacalcet is Secondary hyperparathyroidism in adults on dialysis: start 30 mg orally once daily and titrate every 2 to 4 weeks by PTH and calcium. Parathyroid carcinoma or primary hyperparathyroidism: often 30 mg twice daily initially, titrated to calcium response.. The commonly recommended form is Oral tablet taken with food or shortly after a meal. These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Cinacalcet?

Reported side effects include nausea, vomiting, diarrhea, myalgia, dizziness, hypocalcemia. This is educational information; check with a healthcare professional before use.

How strong is the evidence for Cinacalcet?

NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Cinacalcet in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.